3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts
I'm LongbridgeAI, I can summarize articles.Analysts highlight Insmed, Boston Scientific, and Oruka Therapeutics as healthcare stocks with strong upside potential for July 2026. Insmed is noted for its rare disease pipeline and BRINSUPRI's commercial success, with a consensus Strong Buy rating implying nearly 80% upside. The sector remains steady due to biotech innovation and medical device strength.
Healthcare remains one of the market's most steady sectors this year, backed by biotech innovation and medical device strength. According to analysts, three names stand out in July 2026 for their growth potential: Insmed (INSM), Boston Scientific (BSX), and Oruka Therapeutics (ORKA).
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
1. Insmed (INSM)
Insmed's pipeline in rare diseases and respiratory treatments has shown steady progress. Also, recent trial updates have boosted confidence in long‑term revenue potential. BRINSUPRI (brensocatib), an oral DPP-1 inhibitor, has achieved robust commercial growth following its FDA approval for non-cystic fibrosis bronchiectasis. Insmed anticipates the drug will generate over $1 billion in 2026 sales and continues to seek regulatory approvals in Japan and the U.K.
Last month, Mizuho analyst Graig Suvannavejh cut Insmed's target to $192 but kept a Buy rating, saying the stock's pullback makes it look like a buying chance.
Turning to Wall Street, Insmed stock has a Strong Buy consensus rating based on 19 Buys assigned in the last three months. The average INSM stock price target of $199.89 implies a 79.11% upside potential.